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Respiratory syncytial virus (RSV) infection is an important complication afterhematopoietic cell transplantation
(HCT), and RSV lower respiratory tract disease (LRD) results in substantial early mortality and late airﬂow
obstruction among survivors. Factors associated with poor outcome are unknown. We evaluated the effect of
transplant and treatment factors on overall survival, mortality from respiratory failure, and pulmonary function
among 82 HCT recipients who had RSV LRD between 1990 and 2011. All patients received aerosolized ribavirin.
Inmultivariable analyses, only the use ofmarrow or cord blood as graft source (adjusted hazard ratio [aHR], 4.1;
95% conﬁdence interval [CI], 1.8 to 9.0; P< .001) and oxygen requirement (aHR, 3.3; 95% CI, 1.5 to 6.7; P¼ .003)
remained independently associatedwith overallmortality and death due to respiratory failure (aHR, 4.7; 95% CI,
1.8 to 13; P ¼ .002 and aHR, 5.4; 95% CI, 1.8 to 16; P¼ .002, respectively). Antibody-based treatments, including
intravenous immunoglobulin andpalivizumab,werenot independentlyassociatedwith improvedoutcomeand
didnot alter the associationsof the graft source andoxygen requirements in statisticalmodels. In conclusion, use
of peripheral blood stemcells as graft source and lackof oxygen requirement at diagnosis appear tobe important
factors associatedwith improved survival of HCT recipientswith RSV LRD. These resultsmayexplain differences
in outcomes reported from RSV infection over time and may guide the design of future interventional trials.
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Respiratory syncytial virus (RSV), known as a major cause
of seasonal respiratory viral infection, can cause lower
respiratory tract disease (LRD) in patients after hematopoi-
etic cell transplantation (HCT). RSV infection in this pop-
ulation results in substantial early mortality and has been
associated with late airﬂow decline [1-5]. Outcome studies
are often small in size, and results are difﬁcult to interpret
across sites because factors associated with outcome have
not beenwell deﬁned [6-9]. Candidate variables from smaller
series of respiratory virus disease as well as studies with
other serious pathogens such as aspergillus suggested a role
of lymphopenia, mechanical ventilation, corticosteroids,
copathogens and immune-based therapies on the outcome
[6,10,11].
The purpose of this retrospective study was to examine
the impact of transplant- and treatment-related factors on
overall survival, mortality from respiratory failure, and the
degree of pulmonary function decline in a large cohort of
HCT recipients who received aerosolized ribavirin for RSV
disease.dgments on page 595.
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This was a retrospective cohort study in which patients with RSV LRD
during pretransplantation conditioning or after HCT at the Fred Hutchinson
Cancer Research Center from January 1990 to April 2011were evaluated. RSV
LRD was deﬁned as detection of RSV by shell vial centrifugation culture,
direct ﬂuorescent antibody tests, or conventional culture using a bron-
choalveolar lavage specimen (n ¼ 79), lung biopsy sample (n ¼ 2), or
tracheal mucus (n¼ 1), accompaniedwith lower respiratory tract symptoms
and/or abnormal radiographic ﬁndings [7]. More recent patients were also
positive by polymerase chain reaction.
All patients were treated with aerosolized ribavirin (6 g given as a single
dose over 16 hours or 2 g three times daily over 2 hours) [12]. Patients who
did not receive ribavirin (n ¼ 17), who received oral or intravenous ribavirin
(n ¼ 12), or who received RSV-speciﬁc polyclonal immunoglobulin (n ¼ 5)
were excluded. Intravenous immunoglobulin (IVIG) for treatment (500 mg/
kg three times weekly) was given at the attending physician’s discretion.
Replacement IVIG was given when the level of IgG dropped to <400 mg/dL.
Palivizumab was given to 12 subjects as part of a research study before
U.S. Food and Drug Administration approval [13]. After the drug became
commercially available (1999), we instituted a guideline to routinely
administer palivizumab for RSV LRD in combination with aerosolized riba-
virin (starting in 2002). A single dose of palivizumab (15 mg/kg ideal body
weight) was administered intravenously, except in 1 patient who received 2
doses. This studywas approved by the Institutional Review Board at the Fred
Hutchinson Cancer Research Center.
Deﬁnitions
Underlying disease risk groups at transplantation were classiﬁed as
either standard or high risk. The high-risk group was deﬁned as acute
leukemia, chronic lymphoid leukemia, lymphoma, multiple myeloma,
and solid tumor not in remission, chronic myeloid leukemia in blast crisis,
and all relapsed diseases after HCT. All other stages in any disease as well as
myelodysplastic syndrome were categorized into the standard-risk group.Transplantation.
Table 1
Characteristics of Patients with RSV LRD
All Patients
(n ¼ 82)
Patients Receiving
PFT (n ¼ 28)
Gender
Male 48 (59) 14 (50)
Female 34 (41) 14 (50)
Age at RSV LRD, year
20 6 (7) 2 (7)
21-60 68 (83) 25 (89)
>60 8 (10) 1 (4)
Days between transplantation and
RSV LRD
30 34 (41) 14 (50)
31-365 39 (48) 13 (46)
>365 9 (11) 1 (4)
Transplantation year
1989-1996 24 (29) 5 (18)
1997-2001 33 (40) 15 (53)
2002-2010 25 (31) 8 (29)
Disease risk
Standard 48 (59) 16 (57)
High 34 (41) 12 (43)
Stem cell source
Peripheral blood stem cell 37 (45) 15 (54)
Bone marrow 41 (50) 11 (39)
Cord blood 4 (5) 2 (7)
Donor type
Autologous 15 (18) 2 (6)
HLA-matched related 25 (30) 9 (32)
HLA-matched unrelated 21 (26) 8 (29)
HLA-mismatched 21 (26) 9 (32)
Conditioning regimen
MA þ TBI (> 12Gy) 45 (55) 19 (68)
MA  low TBI 23 (28) 4 (14)
Reduced-intensity conditioning 14 (17) 5 (18)
%FEV1/FVC pre RSV LRD
70 60 (78) 22 (79)
<70 17 (22) 6 (21)
%TLC pre RSV LRD
80 66 (90) 26 (96)
<80 7 (10) 1 (4)
White blood cell counts
>1000  106/L 51 (62) 19 (68)
1000  106/L 31 (38) 9 (32)
Lymphocyte count
>500  106/L 19 (23) 7 (25)
100-500  106/L 38 (46) 14 (50)
<100  106/L 25 (31) 7 (25)
Copathogen
None 54 (66) 20 (71)
Any pathogen 23 (28) 6 (22)
Multiple pathogens 5 (6) 2 (7)
Oxgen at diagnosis
None 33 (42) 12 (44)
2L/minute 12 (15) 7 (26)
>2L/minute 26 (33) 7 (26)
Mechanical ventilation 8 (10) 1 (4)
Steroid use at diagnosis
None 38 (46) 12 (43)
<1 mg/kg 25 (30) 9 (32)
1 mg/kg 19 (23) 7 (25)
Ribavirin use prediagnosis
None 56 (68) 15 (53)
<5 days 10 (12) 5 (18)
5 days 16 (20) 8 (29)
Intravenous immunoglobulin
None 43 (53) 16 (57)
Low-dose* 19 (23) 7 (25)
High-dose 20 (24) 5 (18)
Palivizumab
Yes 38 (46) 15 (54)
No 44 (54) 13 (46)
MA indicates myeloablative conditioning; TBI, total body irradiation; %TLC,
percentage of predicted total lung capacity.
All values are indicated as the number (percentage).
* To maintain levels of >400 mg/dl, as needed.
S. Seo et al. / Biol Blood Marrow Transplant 19 (2013) 589e596590Myeloablative conditioning regimens mainly consisted of high-dose cyclo-
phosphamide and busulfan or fractionated total body irradiation (12.0 or
13.2 Gy). Reduced-intensity conditioning regimens consisted of ﬂudarabine
with a single fraction of total body irradiation (2 Gy). A copathogen was
deﬁned as a signiﬁcant pathogen detected by culture or direct staining
methods obtained from bronchoalveolar lavage specimens or lung biopsy
samples. Death due to respiratory failure was deﬁned as any death caused
exclusively or predominantly by respiratory failure.
Pulmonary Function Testing and Bronchiolitis Obliterans Syndrome
All but 5 patients had undergone pulmonary function testing (PFT)
before the diagnosis of RSV LRD, and these values, mostly before HCT, were
used as baseline values. PFT values after LRD included PFTs obtained at day
60  25 days (early post-LRD) and day 365  90 days (late post-LRD). All
PFTs were performed in accordance with American Thoracic Society
guidelines [14]. Predicted values of forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC), total lung capacity (TLC), and diffusion
capacity of the lung for carbon monoxide (DLCO) were determined using
published equations for children and adults. All DLCO measurements were
corrected for hemoglobin values. Based on the modiﬁed National Institutes
of Health (NIH) guidelines, airﬂowobstructionwas deﬁned as FEV1/FVC< .7,
FEV1 < 75%, and FEV1 decrease of 10% from pre-RSV LRD value [15,16].
Patients with bronchiolitis obliterans syndrome (BOS) were identiﬁed
according to the modiﬁed NIH diagnostic criteria: (1) FEV1/FVC <.7, (2)
FEV1 < 75%, (3) FEV1 decrease of 10% from pretransplantation value,
(4) residual volume >120% of predicted normal or evidence of air trapping,
and (5) absence of respiratory tract infection or pathologic conﬁrmation
[15-17].
Statistical Analysis
Patients were analyzed based on their ﬁrst episode of RSV LRD. The
Wilcoxon rank sum test was used to compare the change of PFT values
before and after RSV LRD. The probability of overall survival was estimated
with the use of the Kaplan-Meier method. The probability of mortality due
to respiratory failure was estimated by cumulative incidence curves, with
death from other reasons as a competing risk. The log-rank test was used for
the comparison between curves. Cox proportional hazards models were
used to evaluate unadjusted and adjusted hazard ratios (HRs) for overall
mortality and mortality due to respiratory failure as well as associated 95%
conﬁdence intervals (CIs).
Use of palivizumab or IVIG was treated as a time-dependent variable.
Covariates evaluated as candidates for risk factors in the multivariable
models included transplantation year, stem cell source, donor type, condi-
tioning regimen, white blood cell count, copathogens, oxygen use at diag-
nosis, ribavirin use prediagnosis, and antibody-based treatment. Variables
with P  .1 in the univariate models were candidates for multivariable
models. Antibody-based treatments were included into the ﬁnal models
regardless of level of signiﬁcance in the univariate analysis. Two-sided
P values <.05 were considered to be statistically signiﬁcant. All statistical
analyses were performed using SAS 9.2 for Windows (SAS Institute, Inc.,
Cary, NC).
RESULTS
Patient Characteristics
A total of 82 patients with RSV LRD who received aero-
solized ribavirin were evaluated. Characteristics of all
patients and the patients receiving PFTs are outlined in
Table 1. The median time to LRD after HCT was 54.5 days
(range, 1 to 2058 days), and the median recipient age was
43 years (range, 3 to 68).
Outcomes
Among all 82 patients, 26 (32%) and 35 (43%) died from
any cause by day 30 and day 100 after RSV LRD, respectively.
Deaths due to respiratory failure by day 30 and day 100 after
RSV LRD were observed in 18 (22%) and 24 (29%) patients,
respectively. The probabilities of overall survival and of death
due to respiratory failure at day 100 after RSV LRD according
to transplantation year are shown in Figure 1A,B. Patients
undergoing HCT in and after 1997 showed an improved
outcome, although the differences did not reach statistical
signiﬁcance (overall survival, P ¼ .074; death due to respi-
ratory failure, P ¼ .283) (Figure 1A,B).
Figure 1. (A) Kaplan-Meier estimate of overall survival according to transplantation year in HCT recipients after RSV LRD (P ¼ .256, for 3-group comparison).
(B) Cumulative incidence of death due to respiratory failure according to transplantation year (P ¼ .605). (C) Kaplan-Meier estimate of overall survival according to
stem cell source in HCT recipients after RSV LRD (P < .001). (D) Cumulative incidence of death due to respiratory failure according to stem cell source (P ¼ .006). (E)
Kaplan-Meier estimate of overall survival according to the oxygen requirement at diagnosis in HCT recipients after RSV LRD (P ¼ .001). (F) Cumulative incidence
of death due to respiratory failure according to the oxygen requirement at diagnosis (P ¼ .002).
S. Seo et al. / Biol Blood Marrow Transplant 19 (2013) 589e596 591Risk Factors for Mortality from All Causes or Respiratory
Failure by 100 Days after RSV LRD
Univariate analyses of risk factors for overall mortality
identiﬁed that the use of bone marrow (BM) as stem cell
source, baseline oxygen requirement of more than 2 L/min,
and white blood cell count of 1000  106/L or less at diag-
nosis are signiﬁcantly correlated with high mortality
(Table 2). The results for death due to respiratory failurewere
similar. Multivariable analyses demonstrated that only the
use of BM or cord blood (CB) as stem cell source and oxygen
requirement remained associated with increased overall
mortality and death due to respiratory failure (Table 3),
which was conﬁrmed in the cohort excluding the 4 patients
receiving CB (data not shown).Overall survival and mortality due to respiratory failure
according to these 2 factors are shown in Figure 2. Day-100
mortality due to respiratory failure among peripheral blood
stem cell transplantation (PBSCT) recipients without oxygen
was 0%, whereas among BM or CB transplantation (BMT/CBT)
recipients who received oxygen, overall mortality was 58%
(Figure 2B). A total of 24 patients required mechanical
ventilation during the clinical course of RSV LRD (including 8
at the time of diagnosis), and 15 of them died from respira-
tory failure by 100 days after RSV LRD. All 4 BMT/CBT
recipients requiringmechanical ventilation at diagnosis died,
compared with 1 of 4 PBSCT recipients (Figure 2C,D).
To examine whether the use of antibody-based treat-
ments were independently associatedwith these 2 outcomes
Table 2
Univariate Analysis of Risk Factors for Mortality from All Causes or Respi-
ratory Failure by Day 100 after RSV LRD
Overall Mortality Mortality from
Respiratory Failure
HR 95% CI P
Value
HR 95% CI P
Value
Transplantation year
1989-1996 1.00 1.00
1997-2001 0.59 0.3-1.3 .180 0.75 0.3-1.9 .548
2002-2010 0.54 0.2-1.3 .155 0.59 0.2-1.7 .327
Stem cell source
Peripheral blood stem
cell
1.00 1.00
Bone marrow 3.94 1.8-8.7 <.001 4.31 1.6-12 .004
Cord blood 1.07 0.1-8.6 .947 1.71 0.2-15 .626
Donor type
Autologous 1.00 1.00
Allogeneic 1.91 0.7-5.4 .222 5.60 0.8-42 .092
Conditioning regimen
MA þ TBI (12 Gy) 1.00 1.00
MA  low TBI 0.78 0.4-1.7 .524 0.34 0.1-1.1 .081
Reduced-intensity
conditioning
0.50 0.2-1.4 .199 0.64 0.2-1.9 .424
White blood cell counts
>1000  106/L 1.00 1.00
1000  106/L 2.29 1.2-4.4 .015 2.16 1.0-4.8 .060
Copathogen
None 1.00 1.00
Any pathogen 1.36 0.7-2.8 .406 0.80 0.3-2.2 .671
Multiple pathogens 1.83 0.5-6.1 .331 2.35 0.7-8.1 .177
Oxygen at diagnosis
None 1.00 1.00
2L/minute 0.71 0.2-3.3 .656 1.58 0.3-8.7 .596
>2L/minute 3.13 1.4-7.1 .006 5.15 1.7-16 .005
Mechanical ventilation 6.21 2.2-18 <.001 11.2 3.0-42 <.001
Ribavirin use pre
diagnosis
None 1.00 1.00
<5 days 0.67 0.2-1.9 .450 0.23 0.0-1.7 .148
5 days 0.43 0.2-1.2 .120 0.44 0.1-1.5 .191
Ab-based treatment as
time-dependent
variable
None/Low-dose 1.00 1.00
High-dose 1.17 0.5-2.8 .727 1.41 0.5-3.9 .510
Palivizumab* 0.74 0.3-1.6 .450 0.76 0.3-2.0 .567
MA indicates conditioning; TBI, total body irradiation; Ab, antibody; FEV1,
forced expiratory volume in 1 second; FVC, forced vital capacity; %TLC,
percentage of predicted total lung capacity; GVHD, graft-versus-host
disease; CMV, cytomegalovirus.
All variables in Table 1 were used for the univariate analysis. Only variables
with P< .2 in any analysis, except for Ab-based treatment, are shown in this
table. The following parameters were not signiﬁcantly associated: gender,
age at RSV LRD, days between transplantation and RSV LRD, diagnosis,
disease risk at transplantation, %FEV1/FVC pre-RSV LRD, %TLC pre-RSV LRD,
lymphocyte count, steroid use at diagnosis, GVHD prophylaxis, recipient
CMV serostatus, and GVHD in lung at RSV LRD.
* This includes 2 patients who received both palivizumab and high-does
intravenous immunoglobulin.
Table 3
Multivariable Analysis of Risk Factors and Treatment Efﬁcacy for Mortality
from All Causes or Respiratory Failure by Day 100 after RSV LRD
Overall Mortality Mortality from
Respiratory Failure
HR 95% CI P Value HR 95% CI P Value
Model 1
Stem cell source
Peripheral blood stem
cell
1.00 1.00
Bone marrow/Cord
blood
4.08 1.8-9.0 <.001 4.73 1.8-13 .002
Oxygen at diagnosis
No 1.00 1.00
Yes 3.12 1.5-6.7 .003 5.39 1.8-16 .002
Model 2
Ab-based treatment as
time-dependent
variable
None/Low-dose 1.00 1.00
High-dose 1.75 0.7-4.2 .216 2.15 0.8-6.1 .148
Palivizumab* 1.04 0.5-2.3 .920 1.10 0.4-2.9 .843
Stem cell source
Peripheral blood stem
cell
1.00 1.00
Bone marrow/Cord
blood
3.86 1.7-8.7 .001 4.44 1.6-12 .004
Model 3
Ab-based treatment as
time-dependent
variable
None/Low-dose 1.00 1.00
High-dose 1.75 0.7-4.3 .221 2.42 0.9-6.9 .097
Palivizumab* 0.99 0.4-2.2 .974 1.07 0.4-2.8 .888
Oxygen at diagnosis
No 1.00 1.00
Yes 2.94 1.3-6.5 .008 5.39 1.8-16 .003
Ab indicates antibody.
The factors with P < .1 in Table 2 were evaluated in the multivariable
models; Ab-based treatments were included regardless of level of signiﬁ-
cance in the univariate models.
* This includes 2 patients who received both palivizumab and high-does
intravenous immunoglobulin.
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and oxygen requirements, we ﬁt several multivariable
models (Table 3). None of these models showed an inde-
pendent effect of antibody-based treatments or a signiﬁcant
change in the effect size of the 2 major risk factors. Addi-
tional models were ﬁt including oxygen levels >2 L or
mechanical ventilation and mechanical ventilation alone,
none of which showed qualitatively different results (data
not shown). Subset analyses restricting the patients trans-
planted between 1997 and 2010, which would decrease the
effect of a time bias, also did not reveal different results
(Table 4). The effect of the receipt of PBSC and lack of oxygenrequirement at diagnosis on overall survival and death due to
respiratory failure are shown in Figure 1C-F.
Changes in Pulmonary Function and BOS
Among the 82 patients, 28 were examined for pulmonary
function at 60 days and/or 1 year after RSV LRD. Most of the
PFT values declined within 2 months after infection; for
some parameters, the decline continued for 1 year (Figure 3).
In %DLco, the decrease was signiﬁcant at 60 days after RSV
LRD (P ¼ .003). The modiﬁed NIH criteria for airﬂow
obstruction were met in 2 of 21 patients at 60 days after RSV
LRD and in 2 of 16 patients at 1 year. Among the 82 patients, 5
were diagnosed as BOS according to the modiﬁed NIH
diagnostic criteria. Four of them had BOS before RSV LRD,
whereas only 1 developed BOS 9 months after RSV LRD.
DISCUSSION
This retrospective cohort study of RSV LRD found that
a favorable outcome is signiﬁcantly associated with the use
of PBSC as a graft source and the absence of requiring oxygen
at the time of diagnosis of RSV LRD. The importance of
respiratory failure at the time of diagnosis on subsequent
clinical outcome has been suggested by other studies [11].
Because oxygen use at diagnosis may serve as a surrogate
indicator of acute lung injury, this observation is plausible.
Perhaps the most important and novel ﬁnding in this report
is that patients after PBSCT had a lower mortality and death
Figure 2. (A) Kaplan-Meier estimate of overall survival according to stem cell source and the oxygen requirement at diagnosis (P  .0001, for 4-group comparison).
(B) Cumulative incidence of death due to respiratory failure according to stem cell source and the oxygen requirement at diagnosis (P  .0001). (C) Kaplan-Meier
estimate of overall survival according to stem cell source and mechanical ventilation requirement at diagnosis (P  .0001). (D) Cumulative incidence of death due
to respiratory failure according to stem cell source and mechanical ventilation requirement at diagnosis (P  .0001).
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CBT. Previous studies demonstrated that patients after PBSCT
have higher numbers of adoptively transferred lymphocytes
and earlier immune reconstitution, resulting in fewer infec-
tions compared with those after BMT [10,18-20]. Although
only very few CBT recipients were included in this analysis,
CBT is also known to have late immune reconstitution
compared with PBSCT or BMT [21-24]. Our observation that
PBSCT recipients have improved survival after documented
RSV LRD suggests that the degree of immunosuppression is
a key factor in the recovery from the disease.
Interestingly, other factors, such as lymphopenia at the
time of diagnosis, the presence of copathogens, baseline lung
function, and antibody treatments, did not appear to be
important in this study. Although palivizumab has shown
a proven prophylactic effect in infants at high risk for bron-
chiolitis, little is known about the treatment efﬁcacy of pal-
ivizumab in adults and HCT recipients with RSV LRD. Some
studies have suggested an improved outcome of RSV infec-
tion after palivizumab treatment; however, the drug is not
approved for this indication, and most studies have been
small and nonrandomized, thereby limiting the ability to
perform multivariable analyses [3,11,25-28]. The current
study suggests that PBSC andmore frequent diagnosis of RSV
LRD at a stage before oxygen dependency, rather than pal-
ivizumab, was likely the important factor in the improved
outcome of RSV disease in recent years. Although Ottolini
et al. demonstrated that palivizumab can reduce viralreplication in lung in an animal model, the complete control
of viral replication required sequential use of multiple doses
of palivizumab [29]. Likewise, intubated infants with RSV
infection showed reduced RSV titers in tracheal aspirates
after palivizumab treatment; however, clinical outcomes
were not affected [30].
Based on these data, we speculate that once RSV-
attributed airway inﬂammation begins [5], palivizumab
alone may not be able to interfere with the inﬂammatory
cascade. In the setting of prophylaxis of RSV LRD, pal-
ivizumab reduced respiratory symptoms, including
wheezing, in premature infants [31]. Therefore, the use of
palivizumab before progression to LRD might theoretically
be beneﬁcial to prevent pulmonary function decline. At this
point, such an effect is hypothetical, and randomized trials
are needed to answer these questions. The development of
newer, more potent RSV monoclonal antibodies such as
motavizumab could potentially be of interest in future
studies, although this new monoclonal was not approved by
the U.S. Food and Drug Administration after trials in high-
risk infants [32,33], and a recent study suggested no
beneﬁt in the treatment setting [34].
The decline in pulmonary function is one of the important
features of RSV LRD [5]. Previous studies have suggested that
respiratory virus infections after lung transplantation stim-
ulate the incidence of BOS [35-38]. Compared with the
incidence rates of BOS (2% to 6%) in recent studies based on
the new NIH diagnostic criteria [17,39], the incidence in our
Table 4
Risk Factors for Mortality from All Causes or Respiratory Failure by Day 100 after RSV LRD in Patients Transplanted between 1997 and 2010 (n ¼ 58)
Risk Factors Overall Mortality Mortality from Respiratory Failure
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Transplantation year
1997-2001 1.00 1.00
2002-2010 0.95 0.4-2.2 .907 0.81 0.3-2.2 .686
Stem cell source
Peripheral blood stem cell 1.00 1.00 1.00 1.00
Bone marrow 3.77 1.5-9.4 .004 4.71 1.9-12 .001 5.16 1.6-16 .005 7.76 2.4-25 <.001
Cord blood 1.06 0.1-8.6 .956 1.85 0.2-17 .581
Conditioning regimen
MA þ TBI (12 Gy) 1.00 1.00
MA  low TBI 0.83 0.3-2.3 .725 0.20 0.0-1.5 .118
Reduced-intensity conditioning 0.78 0.3-2.4 .670 0.91 0.3-2.9 .867
White blood cell counts
>1000  106/L 1.00 1.00
1000  106/L 1.86 0.8-4.3 .147 1.76 0.7-4.7 .262
Copathogen
None 1.00 1.00
Any pathogen 1.10 0.4-2.9 .843 0.71 0.2-2.6 .601
Multiple pathogens 2.22 0.6-7.8 .214 2.81 0.8-10 .118
Oxygen at diagnosis*
None 1.00 1.00 1.00 1.00
2L/minute 0.51 0.1-4.2 .532 1.19 0.1-12 .878
>2L/minute 3.24 1.2-8.8 .020 3.57 1.4-9.0 .007 6.57 1.7-25 .006 7.98 2.2-29 .001
Mechanical ventilation 3.58 0.9-14 .065 5.59 0.9-34 .060
Steroid use at diagnosis
None 1.00 1.00
<1 mg/kg 0.80 0.3-2.1 .645 0.94 0.3-3.1 .913
1 mg/kg 2.00 0.7-5.9 .208 3.19 1.0-11 .057
Ribavirin use prediagnosis
None 1.00
<5 days 0.37 0.1-2.8 .338
5 days 0.25 0.0-1.9 .180
Ab-based treatment as time-dependent varable
None/Low-dose 1.00 1.00
High-dose 1.49 0.4-6.0 .575 1.19 0.3-5.3 .824
Palivizumaby 1.11 0.4-3.4 .856 0.77 0.2-2.5 .671
MA indicates myeloablative conditioning; TBI, total body irradiation; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; %TLC, percentage of
predicted total lung capacity; GVHD, graft-versus-host disease; CMV, cytomegalovirus.
All variables in Table 1were used for the univariate analysis. Only variables with P< .2 in any analysis are shown in this table. The following parameters were not
signiﬁcantly associated: gender, age at RSV LRD, days between transplantation and RSV LRD, donor type, diagnosis, disease risk at transplantation, GVHD
prophylaxis, recipient CMV serostatus, and GVHD in lung at RSV LRD, %FEV1/FVC pre-RSV LRD, %TLC pre-RSV LRD, lymphocyte count. The factors with P< .1 were
evaluated in the multivariable models.
* In the multivariate analysis, oxgen at diagnosis was categorized into 2 groups: none þ 2L/minute and >2L/minute þ mechanical ventilation.
y This includes 2 patients who received both palivizumab and high-dose intravenous immunoglobulin.
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recipients surviving more than 100 days after HCT).
However, considering that our sample size is small and most
patients were diagnosed with BOS before RSV LRD, we have
insufﬁcient information tomake deﬁnitive conclusions about
the association between BOS and RSV LRD.
Our study has strengths and limitations. It includes the
largest outcome cohort of RSV LRD thus far withFigure 3. Percentages of FEV1 (A), TLC (B), and DLCO (C) predicted for each value are
parameters in %FEV1, %TLC, and %DLco are .249, .260, and .001, respectively. *P < .05standardized diagnostic criteria (virologically proven LRD by
conventional methods) and uniform antiviral treatment.
Antibody-based treatments were protocol based for pal-
ivizumab but were given according to the attending physi-
cian’s discretion for IVIG. The nonrandomized nature of the
study is the most important limitation. However, conducting
randomized trials is very difﬁcult for rare diseases such as
RSV LRD in HCT recipients and has failed in several instancesshown at the time point of pre-LRD, day 60, and 1 year after RSV LRD. P for 3
, by Wilcoxon rank sum test.
S. Seo et al. / Biol Blood Marrow Transplant 19 (2013) 589e596 595even when a fully funded multicenter protocol was available
(clinicaltrials.gov NCT00014391). Although this is the only
outcome study of RSV LRD that has performed multivariable
modeling, the statistical power to detect or rule out the
possibility of smaller effects of antibody-based treatments
such as palivizumab was limited. Based on post hoc calcu-
lations, the minimum detectable effect size in our study for
antibody-based treatments would have been a 50% reduction
of mortality. Thus, very large multicenter retrospective
studies are needed to evaluate an effect size of <10% as
suggested by our multivariable models. Whether such
a relatively small effect would be deemed clinically signiﬁ-
cant is unclear given the enormous cost of the treatment
(approximately U.S.$32,000 per 75 kg body weight for drug
acquisition).
Our study also included only a small number of CBT
recipients, which might represent a distinct clinical sub-
group [11]. We analyzed CBT and BMT recipients together in
this study because both groups have comparatively late
immune reconstitution. However, the impact of CB is still
unclear and requires larger numbers of patients. The exclu-
sion of CBT recipients from themajor analyses did not change
the key conclusions of this article. Another limitation is that
the cases occurred over 2 decades, which may have led to
differences in supportive care practices and the timing of
bronchoscopic evaluation. We accounted for this by
including the year of transplantation and the degree of lung
injury in our models.
In conclusion, our study identiﬁed 2 signiﬁcant factors
that are associated with improved outcome of RSV LRD in
HCT recipients: the use of PBSC as the graft source and the
lack of oxygen requirement at the time of diagnosis of LRD.
Patients who had both factors at the time of diagnosis at RSV
LRD had very favorable outcomes with aerosolized ribavirin
treatment, which was administered to all patients
(Figures 1C-F). These data could explain differences in
outcome data reported over time and from different centers
around the world. They could also serve as adjustment
factors inmultivariablemodels in future outcome analyses or
to stratify patients in future randomized treatment trials.
Antibody therapies had no apparent effect on these
associations, but our sample size prevented us from ruling
out possible small effects. Multicenter studies are needed to
validate these ﬁndings. Overall, our data suggest that the
observed improvement in outcome of RSV disease in recent
years is likely due to increased use of PBSC as graft source
and the associated improved immune reconstitution, and to
the increased early initiation of antiviral treatment before
the onset of lung injury.
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